McAdoo SP, Pusey CD. Anti-glomerular basement membrane disease. Clin J Am Soc Nephrol. 2017;12:1162–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alchi B, Griffiths M, Sivalingam M, Jayne D, Farrington K. Predictors of renal and patient outcomes in anti-GBM disease: clinicopathologic analysis of a two-centre cohort. Nephrol Dial Transplant. 2015;30:814–21.

Article  CAS  PubMed  Google Scholar 

McAdoo SP, Tanna A, Hrušková Z, et al. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int. 2017;92:693–702.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int. 2021;100:753–79.

Article  PubMed  Google Scholar 

Jain R, Dgheim H, Bomback AS. Rituximab for anti-glomerular basement membrane disease. Kidney Int Rep. 2018;4:614–8.

Article  PubMed  PubMed Central  Google Scholar 

Gulati K, Edwards H, Prendecki M, et al. Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 2021;100:1316–24.

Article  CAS  PubMed  Google Scholar 

Furuta S, Nakagomi D, Kobayashi Y, et al. Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial. JAMA. 2021;325:2178–87.

Article  CAS  PubMed  Google Scholar 

Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382:622–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jayne DRW, Merkel PA, Schall TJ, Bekker P, ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384:599–609.

Article  CAS  PubMed  Google Scholar 

Gabilan C, Pfirmann P, Ribes D, et al. Avacopan as first-line treatment in antineutrophil cytoplasmic antibody-associated vasculitis: a steroid-sparing option. Kidney Int Rep. 2022;7:1115–8.

Article  PubMed  PubMed Central  Google Scholar 

Alvarez L, Kambham N, Su R. Renal improvement and remission in a patient with refractory ANCA-associated vasculitis treated with avacopan. J Nephrol. 2023;36:2365–70.

Article  PubMed  PubMed Central  Google Scholar 

Cortazar FB, Cerda J, Dhanani R, Roglieri J, Santoriello D. Avacopan in patients with rapidly progressive glomerulonephritis requiring dialysis. Kidney Int Rep. 2023;8:1687–91.

Article  PubMed  PubMed Central  Google Scholar 

Cortazar FB, Niles JL, Jayne DRW, et al. Renal recovery for patients with ANCA-associated vasculitis and low eGFR in the ADVOCATE trial of avacopan. Kidney Int Rep. 2023;8:860–70.

Article  PubMed  PubMed Central  Google Scholar 

Caillard P, Vigneau C, Halimi JM, et al. Prognostic value of complement serum C3 level and glomerular C3 deposits in anti-glomerular basement membrane disease. Front Immunol. 2023;14:1190394.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qu Z, Cui Z, Liu G, Zhao MH. The distribution of IgG subclass deposition on renal tissues from patients with anti-glomerular basement membrane disease. BMC Immunol. 2013;14:19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fischer EG, Lager DJ. Anti-glomerular basement membrane glomerulonephritis: a morphologic study of 80 cases. Am J Clin Pathol. 2006;125:445–50.

Article  PubMed  Google Scholar 

Oba R, Kanzaki G, Sasaki T, et al. Long-term renal survival in antineutrophil cytoplasmic antibody-associated glomerulonephritis with complement C3 deposition. Kidney Int Rep. 2021;6:2661–70.

Article  PubMed  PubMed Central  Google Scholar 

Sethi A, Grande J, Specks U, Fervenza FC. Proteomic profile of uninvolved versus crescentic glomeruli in MPO-ANCA-associated vasculitis. Clin Kidney J. 2023;16:1180–2.

Article  PubMed  PubMed Central  Google Scholar